Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 22, Issue 7, Pages 955-959Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458515602337
Keywords
Neuromyelitis optica; rituximab; refractory; disability; body mass index
Categories
Funding
- Association pour la Recherche sur la Sclerose en Plaques (ARSEP)
- France's Agence Nationale de la Recherche [ANR-10-COHO-002, 2011-RARE-002-01]
Ask authors/readers for more resources
Background: Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy. Objective: The purpose of this study was to assess RTX as a maintenance therapy in RNMO. Methods: Out of a total of 305 NMO cases from a population-based cohort, 21 RNMO patients received RTX during a mean follow-up period of 31 months. Results: After RTX, 11 patients (52.3%) were relapse free, meaning that 47.7% were refractory to RTX. The mean annualized relapse rate decreased from 1.3 to 0.4 (p<0.001) and median EDSS from 5 to 3 (p=0.02). Body mass index (BMI) was predictive of EDSS worsening. Conclusions: RTX is an effective and well-tolerated treatment in RNMO. BMI could be a predictive factor for efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available